Tafinlar (dabrafenib) — Cigna
Thyroid Carcinoma, Anaplastic
Initial criteria
- Patient has locally advanced or metastatic anaplastic disease
- Patient has BRAF V600 mutation-positive disease
- Medication will be taken in combination with Mekinist (trametinib tablets or oral solution)
Approval duration
1 year